Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01094639 · ClinicalTrials.gov registry record · NA

Periodontal Infection and Systemic Inflammation in Renal Patients

A NA study, sponsored by UConn Health.

Completed
Registry status
NA
Development phase
52
Enrollment target

NCT01094639: Completed NA study, sponsored by UConn Health.

NCT01094639 is a NA study that has completed, run by UConn Health. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01094639, a NA study, has completed, sponsored by UConn Health.

COMPLETED
Registry status
NA
Development phase
52 participants
Enrollment target

Study Summary

The purpose of this study is to examine the role of gum disease in affecting the long term prognosis of renal patients. This disease if untreated causes inflammatory response throughout the body. If the subject has gum disease, he/she will be randomly assigned to one of the two treatment groups. The study investigates what happens to inflammatory markers in blood and saliva after you are treated for gum disease.

Primary Outcome

IL-6 and CRP are markers of systemic inflammation and may improve at the end of gum treatment.

Interventions

  • PROCEDURE Scaling root planing
  • PROCEDURE Supragingival Prophylaxis

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2009-08
Est. Completion 2015-08
Phase NA
UConn Health

178 total trials

What the finished NCT01094639 record still lists

NCT01094639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Scaling root planing is the first listed.

NCT01094639 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01094639 about?

NCT01094639 is a clinical study titled "Periodontal Infection and Systemic Inflammation in Renal Patients". The purpose of this study is to examine the role of gum disease in affecting the long term prognosis of renal patients. This disease if untreated causes inflammatory response throughout the body. If the subject has gum disease, he/she will be randomly assigned to one of the two treatment groups. The...

What is the current status of trial NCT01094639?

This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2009-08. Estimated completion is 2015-08.

What interventions are being tested in trial NCT01094639?

The interventions under investigation include: Scaling root planing (PROCEDURE), Supragingival Prophylaxis (PROCEDURE).

Who is sponsoring clinical trial NCT01094639?

This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01094639's enrollment target sits among peer trials

52 1272nd of 2000 higher than 722 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01094639, the US trial registry maintained by the National Library of Medicine. NCT01094639 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.